Plasma levels of IL-6 in patients with untreated major depressive disorder: Comparison with catecholamine metabolites

10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD). Aim: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD. Participants and methods: A total of 148 patients (male/female 65/83, age 49.5±12.1 years) who met the criteria for MDD based on the Diagnostic and Statistical Manual of Mental Disorders IV and 40 participants as healthy controls (HC; male/female 23/17, age 44.0±10.5 years) were enrolled in the present study. Plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) were analyzed using high-performance liquid chromatography, and plasma IL-6 levels were measured using ELISA. Results: No correlations were observed among plasma IL-6 levels, MHPG levels, and HVA levels in patients with MDD. Plasma IL-6 levels in patients with MDD were significantly higher than in the HC. A positive correlation was found between plasma IL-6 levels and Hamilton Rating Scale for Depression-17 scores. Conclusion: No correlations existed between plasma IL-6 levels and plasma catecholamine metabolite levels in patients with MDD, and the severity of depressive state was related to plasma IL-6 levels in MDD.

Cite

CITATION STYLE

APA

Yoshimura, R., Kishi, T., & Iwata, N. (2019). Plasma levels of IL-6 in patients with untreated major depressive disorder: Comparison with catecholamine metabolites. Neuropsychiatric Disease and Treatment, 15, 2655–2661. https://doi.org/10.2147/NDT.S195379

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free